NCL urges FDA and FTC to investigate potentially false advertising claims made by a recent-FDA approved anti-wrinkle drug

October 26, 2022

Media contact: National Consumers League – Katie Brown,, (202) 207-2832

Washington D.C.— The National Consumers League (NCL) recently submitted a letter to the Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) urging the agencies to look into misleading advertising claims made by a recent FDA-approved anti-wrinkle drug called DAXXIFY™ (DaxibotulinumtoxinA-lanm).

Revance Therapeutics, Inc., the manufacturer of DAXXIFY™, is promoting the drug’s ability to reduce the appearance of facial lines and wrinkles in about half of its users for about six months. However, FDA-required labeling verifies that roughly one-third of users experience no or mild facial lines for six months after injection – a 20 percent discrepancy from the company’s claim.

NCL believes this discrepancy is concerning and warrants a closer investigation. Moreover, a study mentioned in the company’s press release appears to make inaccurate claims about its results, according to NCL.

We ask that if our concerns are warranted, the FDA and the FTC should hold Revance Therapeutics to accurate claims and insist that the company correct anything deceptive in their advertising, says NCL Executive Director Sally Greenberg.

To view the full letter, click here.


About the National Consumers League (NCL)

The National Consumers League, founded in 1899, is America’s pioneer consumer organization. Our mission is to protect and promote social and economic justice for consumers and workers in the United States and abroad. For more information, visit